Nasdaq
$4.63▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $35.6MShares out 7.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 9.9Pre-market26.09.09 20:406-KKey event#●●●#●●●
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals has rebranded to 'EoCene Ltd.' and will change its Nasdaq ticker symbol to 'EOCN'. The company has terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville and regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing.…more
$4.63+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.8Pre-market26.09.08 19:086-KKey event
Galmed Pharmaceuticals Ltd.
On September 3, 2026, Galmed Pharmaceuticals was notified by Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company maintained a closing bid price of at least $1.00 per share for 10 consecutive trading days from August 20 to September 2, 2026, resolving the delisting deficiency matter.…more
$4.63+0.00%vs prev closeView filingShare - 9.4Pre-market26.09.04 13:15filedEFFECTOther
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. has received SEC effectiveness for its registration statement as of September 3, 2026. This filing confirms the completion of the legal process required for the company's proposed securities offering or capital raise.…more
$4.63+0.00%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.9Pre-market26.09.09 20:32#●●●
Galmed Pharmaceuticals Rebrands to Eocene and Changes Ticker to EOCN
Galmed Pharmaceuticals will rebrand to Eocene and change its Nasdaq ticker symbol to EOCN effective September 10. The company also announced the termination of its standby equity purchase agreement with Yorkville.…more
$4.63+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.19Pre-market26.08.19 21:55
●●●●●●●● ●●●●● ●●●●●●
Trading for a specific stock was temporarily halted and has now resumed following the release of news. Investors should review the latest company disclosures.…more
$4.63+0.00%vs prev closeShareBenzinga - 8.19Pre-market26.08.19 20:04
●●●●●●●● ●●●●● ●●●●●●
Galmed Pharmaceuticals' subsidiary, Colospan, has successfully completed a feasibility study for a new platform designed to quantitatively assess colon tissue quality during surgery. While the study confirms technical feasibility, the project remains in the development phase, warranting a neutral outlook.…more
$4.63+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report